Academic Journal
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
| Title: | First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis |
|---|---|
| Authors: | Domenico Ciliberto, Giulio Caridà , Nicoletta Staropoli, Caterina Romeo, Grazia Maria Arillotta, Cristina Napoli, Luigia Gervasi, Francesco Luciano, Caterina Riillo, Pierfrancesco Tassone, Pierosandro Tagliaferri |
| Source: | Heliyon, Vol 9, Iss 8, Pp e18696- (2023) |
| Publisher Information: | Elsevier, 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Science (General) LCC:Social sciences (General) |
| Subject Terms: | HCC, Advanced hepatocellular carcinoma, TKI, ICI, Sorafenib, Lenvatinib, Science (General), Q1-390, Social sciences (General), H1-99 |
| More Details: | The rapid development of novel therapeutic options for advanced hepatocellular carcinoma (aHCC) has generated some uncertainty about the rational choice of the systemic upfront treatment. So far, a variety of therapeutic strategies have been investigated, including the combination of immunecheckpoint inhibitors and anti-VEGF. To identify the treatment that should be preferred as front-line approach, we compared the efficacy and toxicity of a variety of therapeutic strategies. With this aim, we performed a systematic review and a meta-analysis of randomized clinical trials. OS, PFS, ORR and tolerability outcomes were considered, and for each outcome the treatment ranking was evaluated by the surface under the cumulative rankings (SUCRAs). Combination of Camrelizumab + Rivoceranib scored the best in OS, followed by Sintilimab + Bevacizumab, whereas Lenvatinib + Pembrolizumab showed higher probability to be the best treatment in PFS and Sintilimab + Bevacizumab performed best in ORR. Finally, Durvalumab is the most tolerated treatment. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2405-8440 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2405844023059042; https://doaj.org/toc/2405-8440 |
| DOI: | 10.1016/j.heliyon.2023.e18696 |
| Access URL: | https://doaj.org/article/fb2e6fd54a394d6ab96df15017f50d9f |
| Accession Number: | edsdoj.fb2e6fd54a394d6ab96df15017f50d9f |
| Database: | Directory of Open Access Journals |
| ISSN: | 24058440 |
|---|---|
| DOI: | 10.1016/j.heliyon.2023.e18696 |
| Published in: | Heliyon |
| Language: | English |